Interleukin-17A Augments Mesenchymal Stem Cell Function


One of the biggest problems with organ transplantations is that the immune system can reject the transplanted tissue. Transplant rejection requires the patient to go through another traumatic surgery, and if another organ is not available, then they might very well die. Is there a way to reduce organ rejection?

Our bodies have on our cell surfaces a series of “bar codes” that are the result of “Major Histocompatibility Antigens” or MHC proteins. These proteins are encoded by genes that vary extensively. Therefore, each person has a distinct combination of cell surface proteins that decorate the outside of their cells. If your immune system finds cells that have a different set of MHCs that what you were born with, the immune system, which has been “taught” to accept your own proteins and reject different proteins, will attack and destroy the transplanted tissue. This is known as “Graft vs Host disease” or GvHD. To avoid GvHD, transplant physicians try to find organs that match your own tissue type as closely as possible. However, it is virtually impossible to find organs that perfectly match your own. Even if the patient is given anti-rejection drugs, sometimes the immune system begins to reject the transplanted organ. Is there a way around this?

Mesenchymal stem cells (MSCs) have the ability to suppress unwanted immune responses. If MSCs are pre-treated with cytokines, they can do this even better. Typically, MSCs are pre-treated with a molecule called interferon-γ. This molecule stimulates MSCs and causes then to suppress the immune response, but it also causes MSCs to express proteins that cause them to be rejected by the immune system. Thus interferon-γ seems to cause problems that prevent the MSCs from working properly.

In a really beautiful paper by Kisha Sivanathan in the Coates lab at the School of Medical Sciences, Adelaide, Australia and her colleagues, showed that pre-treating human MSCs with interleukin-17A did a better job at stimulating MSCs without sensitizing the cells to the immune system.

When Sivanathan and her co-workers treated human bone marrow-derived MSC with interleukin-17A, this molecule enhanced the ability of MSCs to suppress the immune response without making the MSCs subjects for rejection by the immune system.  These interleukin-17A-treate MSCs (MSC-17s) showed no induction or upregulation of molecules that the immune system reacts against (MHC class I, MHC class II, and T cell costimulatory molecule CD40), and the the interleukin-17A-treated MSCs maintained normal MSC morphology and made all the common MSC markers.

When MSC-17s were placed in culture with activated human T cells, the MSCs-17s potently suppressed T cell proliferation.  Additionally, MSC-17s prevented activated T-cells from making the whole cocktail of molecules they normally make once they are activated.

Not all T-cells are created equal. There is a group of T-cells called “regulator T-cells” or T-regs for short. T-regs tend to down regulate the immune response. It turns out that MSCs-17s turn on T-regs and stimulate them to potently suppress T-cell activation. They do this without inducing immunogenicity in the MSCs.

Thus, pre-treating MSCs with interleukin-17A represents a superior way for stimulate MSCs to suppress T cell activity in clinical situations.  Dr. Coates and his colleagues are hopeful that this protocol can be the subject of clinical trials in the near future.

Advertisements

Published by

mburatov

Professor of Biochemistry at Spring Arbor University (SAU) in Spring Arbor, MI. Have been at SAU since 1999. Author of The Stem Cell Epistles. Before that I was a postdoctoral research fellow at the University of Pennsylvania in Philadelphia, PA (1997-1999), and Sussex University, Falmer, UK (1994-1997). I studied Cell and Developmental Biology at UC Irvine (PhD 1994), and Microbiology at UC Davis (MA 1986, BS 1984).